Profit growth significantly outpaced revenue expansion in Q2 FY2026, driven by the QSC acquisition and improved operating leverage. The company delivered 26% EPS growth while generating strong operating cash flow to support capital allocation priorities.
Key Takeaways
•Revenue rose 4.9% to $1.06 billion, driven by the QSC acquisition and higher net sales of Distech products in the AIS segment.
•Operating income surged 20.7% to $133.0 million, reflecting higher gross profit that partially offset increased SD&A expenses and special charges.
•Diluted EPS jumped 26.1% to $3.09, significantly outpacing revenue growth through strong operating leverage.
•Gross margin expanded to 49.3%, contributing to an operating margin of 12.6% as profitability improvements flowed through the income statement.
•Free cash flow reached $188.1 million, supported by $229.9 million in net cash from operating activities minus $41.8 million in capital expenditures.
Transformational year marked by deconsolidation of Falcon Copper Corp, driving profitability through non-cash gain amid continued exploration advancements with Nuton and ongoing cash management challenges.
Pre-revenue VitaSpring narrowed its Q1 net loss by 28.8% year-over-year to -$216.8K through reduced operating expenses, reflecting disciplined cost management in this development-stage biotech, though liquidity needs persist via related-party support and planned financings.
Key Takeaways
•Net loss improved 28.8% to -$216.8K from -$304.6K YoY as operating expenses decreased, consistent with management's focus on expense reduction.
•No revenue recognized in Q1 FY2025, matching prior year at $0.00, during strategic evaluation of stem cell commercialization and regulatory matters.
•Operating cash use declined to -$4K from -$27.9K YoY, signaling better cash preservation amid ongoing operational funding needs.
•Diluted EPS remained at $0.00, unchanged from prior year, reflecting the absence of profitability in this early-stage biomedical firm.
•Management plans equity financing, partnerships, and related-party support to fund operating expenses and obligations as they come due.
•Additional capital deemed necessary to support operations over the next twelve months per management's assessment.
A transformative year defined by the strategic pivot to the SemiCab AI logistics platform, where acquisition-driven revenue growth was eclipsed by negative gross margins and substantial operating losses, raising going concern doubts.
Key Takeaways
•Revenue declined 81% to $4.4M from $23.5M, reflecting the strategic divestiture of the legacy Singing Machine business and the partial-year contribution from the May 2025 SMCB acquisition.
•Gross margin collapsed to -29.9% as freight, handling, and servicing costs from the new SMCB operations exceeded revenue, signaling significant unit economics pressure during the transition.
•Operating loss narrowed 43% to -$7.9M, demonstrating improved cost discipline relative to the prior year despite the challenging revenue mix.
•Net loss improved 35% to -$15.9M, with the year-over-year reduction driven by operational changes and expense management.
•Diluted EPS improved 98% to -$6.41 from -$353.87, reflecting the substantial reduction in per-share losses following the company's strategic repositioning.
Solid revenue growth of 7.1% to $611.0M driven by data solutions and workstations was offset by profitability pressures from higher employee compensation costs outpacing topline expansion.
Key Takeaways
•Revenue increased 7.1% to $611.0M, driven by data solutions, workstations and middle office solutions, partially offset by business disposition.
•Gross profit rose 4.4% to $314.3M as revenue growth was partially offset by higher employee compensation and other cost of services expenses.
•Operating income slightly declined to $185.0M with margin contracting to 30.3% from higher compensation costs relative to revenue growth.
•Net income decreased 8.1% to $133.1M and diluted EPS fell 4.5% to $3.59, reflecting operating pressures.
•Net cash from operating activities strengthened to $333.0M, supporting ongoing investments in data ecosystem expansion.
•Gross margin of 51.4% reflects cost of services growth from merit-driven compensation increases outpacing revenue.
DynaResource achieved a dramatic financial turnaround in FY2025, transitioning from significant losses to profitability through operational improvements and higher gold prices, though liquidity challenges and legal contingencies create material uncertainty about its ability to continue as a going concern.
Key Takeaways
•Revenue grew 25.7% to $58.5 million, driven by an increase in net revenue per ounce, partially offset by a decrease in gold ounces sold.
•Operating income swung to $9.7 million from a $6.9 million loss, a 239.4% improvement, reflecting revenue growth and cost management including capitalized mine development costs.
•Net income turned positive at $3.8 million from an $8.1 million loss, a 146.9% improvement, as the company transitioned to a Production Stage issuer under S-K 1300.
•Operating cash flow improved to $5.8 million from an $8.0 million outflow, generating $3.1 million in free cash flow after $2.6 million in capital expenditures.
•The company faces negative working capital that worsened year-over-year, raising substantial doubt about its ability to continue as a going concern.
•Management anticipates 2026 revenue growth from higher-grade feed material, increased processing throughput, and higher gold prices as part of ongoing exploration and project optimization.
FY2025 marked a strategic pivot for Sono Group, transitioning from legacy solar operations to a digital asset treasury strategy, resulting in a significant operating loss offset by non-operating gains, with future performance now entirely dependent on the success of this new high-risk venture.
Key Takeaways
•Revenue of $149K was generated from solar solutions, but a substantial operating loss of -$7.7M reflects the high costs and inefficiencies of the legacy business model.
•Net income of $4.0M was positive, a sharp decline from the prior year, highlighting a divergence from core operational performance driven by non-operating factors.
•The company's operating cash flow was -$7.3M, indicating ongoing cash consumption from operations during the period.
•Management terminated funding to its solar subsidiary in March 2026, pivoting to a Bitcoin-focused Treasury Strategy aimed at generating future cash flow and reducing operating losses.
•The company's ability to continue as a going concern is subject to significant uncertainty, dependent entirely on the success of its new and unproven digital asset strategy.
•Increased expenses were driven by commercialization efforts, including higher personnel and marketing costs to establish new partnerships, as part of the final phase of solar operations.
Klotho Neurosciences reported a wider operating and net loss in FY2025, reflecting continued investment in its pre-revenue pipeline and public company infrastructure, with cash burn accelerating as expected during development.
Key Takeaways
•Operating loss expanded to $7.1M from $5.5M due to higher R&D, G&A, and professional fees, consistent with pipeline advancement and post-merger public company costs.
•Net loss increased 71.6% year-over-year to $10.6M, driven by higher operating expenses, interest expense, and a settlement charge, partially offset by other income.
•Diluted EPS improved to -$0.22 from -$0.32, reflecting both the net loss increase and a larger share count following equity financing activities.
•Net cash used in operating activities nearly doubled to $5.9M, primarily due to rising operational expenses tied to expanding development efforts.
•The company remains pre-revenue and dependent on future equity or debt financing to fund operations, as highlighted in management’s liquidity commentary.
•Cash and working capital stood at $7.2M and $7.2M respectively as of December 31, 2025, providing near-term runway but subject to ongoing burn.
FY2025 marked by 79% revenue decline to $1.9M from reduced customer orders and supply chain constraints, offset by 29% narrower operating losses to -$9.0M through cost discipline amid persistent going concern uncertainties.
Key Takeaways
•Revenue fell 79% to $1.9M as customers reduced orders and procurement slowed during the year.
•Gross profit dropped 99% to $24K with margins compressing to 1.2%, signaling severe volume-related cost pressures.
•Operating loss improved 29% to -$9.0M, reflecting effective expense management relative to lower revenue base.
•Net loss narrowed 16% to -$10.5M with EPS improving 87% to -$2.28, driven by operational cost controls.
•Operating cash use eased to -$4.2M from prior year, supporting ongoing investments in supply network growth.
•Management plans revenue enhancement projects, deferred capex, and expense cuts to address going concern doubts.
Jupiter Neurosciences faced a challenging fiscal year with escalating operating losses and negative cash flow, intensifying liquidity pressure as it invested in clinical development while launching its Nugevia consumer brand, raising substantial doubt about its ability to continue as a going concern.
Key Takeaways
•Revenue of $21.8K from the new Nugevia consumer line launch, which began direct-to-consumer sales in the second half of 2025.
•Net loss deepened to -$8.6M (YoY -254.4%) with negative operating cash flow of -$5.4M, intensifying liquidity pressure.
•Operating loss widened to -$8.9M (YoY -188.2%), reflecting increased investment in clinical development and public company operations.
•Management cited substantial doubt about the company's ability to continue as a going concern due to insufficient cash for planned operations.
•The company is preparing for a Phase IIa clinical trial for Parkinson's Disease, which received final IND approval by the FDA in November 2025 and is expected to start in the second quarter of 2026.
Revenue declined 6.2% to $343.0M amid broad-based demand weakness and component supply constraints, yet profitability surged with operating income up 38.9% to $25.7M and net income soaring 363.4% to $37.5M due to cost efficiencies and our Fab-Light model.
Key Takeaways
•Revenue was $343.0M, down 6.2% from $365.5M as Optimized LED net sales decreased reflecting broad-based demand decline across the business.
•Gross profit was $93.7M, down 10.5% from $104.6M, with gross margin of 27.3% pressured by extended component lead times affecting shipment timing and product mix.
•Operating income rose 38.9% to $25.7M from $18.5M, supported by the Fab-Light business model contributing to overall margin expansion.
•Net income increased 363.4% to $37.5M from $8.1M, with diluted EPS of $0.58 versus $0.09, reflecting improved operating leverage.
•Operating cash flow remained stable at $86.0M, generating $81.6M free cash flow after $4.5M capital expenditures, funding principal uses including working capital and other operating expenses.
Conagra Brands delivered strong net income growth in Q3 FY2026, though operating cash flow declined as the company navigates persistent inflation-driven pricing pressures and consumer volume softness across segments.
Key Takeaways
•Net income increased 37.7% year-over-year to $199.8 million, reflecting improved profitability despite a challenging operating environment.
•Free cash flow was $581.4 million, generated from operating activities of $895.6 million less capital expenditures of $314.2 million, supporting continued business investments.
•The company continues to make investments in business and operating facilities through capital expenditures while maintaining access to sufficient liquidity from operating cash flows and credit facilities.
•Persistent weak consumer sentiment, commodity cost fluctuations, and input cost inflation continue to impact the industry, with expectations for continued volatility in costs of goods sold.
Tilray Brands significantly reduced its net loss by 88% year-over-year to -$25.2 million, reflecting a shift from prior-year impairment charges to a focus on operational execution. Operating cash burn also improved, signaling progress in financial stabilization despite ongoing recessionary headwinds in Europe.
Key Takeaways
•Net loss narrowed 88% to -$25.2M, compared to -$213.2M in the prior year, as the company lapped substantial non-cash impairment charges.
•Operating cash flow improved to -$31.8M from -$82.0M year-over-year, indicating enhanced efficiency in cash management.
•Distribution revenue growth was driven by competitive pricing strategies and a focus on higher-velocity SKUs, alongside favorable foreign exchange impacts.
•Management remains focused on portfolio optimization, including the integration of BrewDog Ireland, to strengthen its beverage segment footprint.
•In Europe, the company expects cannabis legalization to gain traction despite slower-than-expected progress due to political and economic uncertainty.
FY2025 delivered $3.4M revenue with gross margin expansion to 57% from scheduling efficiencies, but operating losses of -$3.6M and net losses of -$7.0M from crypto and intangible impacts drove intensified cash burn of -$3.8M.
Key Takeaways
•Revenue reached $3.4M as the Company focused on retaining paid subscribers and converting registered users.
•Gross profit was $1.9M with 57.0% margin, up slightly from 56% in 2024 due to improved scheduling efficiency of teaching staff and optimized class sizes that cut cost of revenues.
•Operating income was -$3.6M (-106.7% margin), reflecting challenges in controlling costs and expenses amid public company transition.
•Net cash from operating activities was -$3.8M with $0 capex, yielding free cash flow of -$3.8M as subscriber retention remains key to future profitability.
•The Company enhanced class scheduling to align educator availability with student demand, reducing idle time and compensation costs without affecting instructional quality.
A transitional year defined by strategic portfolio reshaping and leadership changes, with improved consolidated profitability despite revenue declines across most businesses.
Key Takeaways
•CEO transition completed with Joseph Levin departing March 31, 2025; Barry Diller resumed direct leadership without appointing a new CEO.
•Consolidated operating income and Adjusted EBITDA improved in 2025 despite revenue declines across most businesses.
•Completed Angi spin-off on March 31, 2025 and initiated sale process for Care.com and other non-core businesses.
•Board approved updated director compensation arrangements effective June 2025, increasing committee retainers.
Exceptional growth year fueled by aggressive execution and acquisitions, delivering strong ARR expansion and profitability gains ahead of a go-private merger with top private equity firms.
Q1 revenue declined 2.2% to $80.3M amid softer retail and wholesale demand, driving operating income down 52.9% to $1.2M despite stable gross margins of 56.2% and flat SG&A expense ratios through operational efficiencies.
Key Takeaways
•Operating income fell 52.9% to $1.2M or 1.4% of sales from $2.5M prior year, reflecting reduced sales leverage substantially offset by warehouse and delivery efficiencies holding SG&A percentage flat.
•Net income declined 39.8% to $1.1M with diluted EPS of $0.13 versus $0.21 last year, driven by lower operating results.
Q3 revenue edged up 8.9% to $11.3B amid inventory liquidation efforts, delivering gross margin expansion to 40.2% but driving sharp net income decline of 34.5% to $520M due to markdowns, returns, and regional pressures.
Key Takeaways
•Revenue increased 8.9% to $11.3B from $11.3B, reflecting modest growth offset by Greater China traffic declines and Converse brand reset.
•Gross profit declined 3.1% to $4.5B with 40.2% margin from lower inventory obsolescence reserves amid liquidation through markdowns.
•Net income fell 34.5% to $520M and diluted EPS dropped 35.2% to $0.35, pressured by higher discounts, sales returns, and wholesale promotions.
•Capital expenditures rose to $546M from $330M, generating $685M free cash flow while creating capacity for new product.
•Lower ASP per pair stemmed primarily from channel mix, partially offset by product mix and strategic pricing.